Intellia Therapeutics price target lowered to $50 from $90 at Truist
Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.
What is William Blair’s Estimate for NTLA FY2029 Earnings?
Equities researchers at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Intellia ...
Leerink Partnrs Weighs in on NTLA Q1 Earnings
Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink ...
Le Lézard5h
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S(NVO) Shareholders
Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") of a class action securities lawsuit.
CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)
CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...
Le Lézard23h
Statement from the Minister of Diversity, Inclusion and Persons with Disabilities on the Canada Disability Benefit
The Minister of Diversity, Inclusion and Persons with Disabilities, Kamal Khera, issued the following statement today regarding the Canada Disability Benefit: "I am very proud to announce that the ...